Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509976 | 0.89 | MEN1 (0.64) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8141144 | 0.85 | POLB (1.00) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL19992618 | 0.84 | POLB (0.68) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5804324 | 0.83 | SMN1; SMN2 (0.59) | POLBTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL14578751 | 0.83 | POLB (0.85) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL2093671 | 0.81 | POLB (0.76) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL3027410 | 0.81 | CYP1A1 (0.60) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2093668 | 0.81 | POLB (0.76) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL2625088 | 0.81 | POLB (0.76) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL7932235 | 0.80 | MAPT (0.62) | TDP1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230313030-A1 | PHOTOACTIVE ORGANIC LIGANDS AND METHODS FOR RADIATION PATTERNING OF NANOPARTICLES FOR FORMATION OF HIGH QUANTUM YIELD DOWNCONVERTER MATERIALS | NanoPattern Technologies, Inc. | 2023-10-05 | — | — | US | disclosed |
| US-20230313030-A1 | PHOTOACTIVE ORGANIC LIGANDS AND METHODS FOR RADIATION PATTERNING OF NANOPARTICLES FOR FORMATION OF HIGH QUANTUM YIELD DOWNCONVERTER MATERIALS | NanoPattern Technologies, Inc. | 2023-10-05 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | POLB 1429/4885HDAC3 258/4885HDAC1 91/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | POLB 1429/4885HDAC3 258/4885HDAC1 91/4885 |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885HDAC3 1109/4885HDAC1 1981/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885HDAC3 1109/4885HDAC1 1981/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | POLB 3959/4885HDAC3 667/4885HDAC1 558/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885HDAC3 1109/4885HDAC1 1981/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | POLB 3799/4885HDAC3 4202/4885HDAC1 4782/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | POLB 3536/4885HDAC3 1109/4885HDAC1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.